Table I.
Characteristic | Na (Nb) | AMc (SE) | Range | GMd (SE) |
---|---|---|---|---|
SI (%) | 1,140 (195) | 78.7 (1.0) | 39–135 | |
DLCs (pg TCDD-EQ/L) | 1,140 (195) | 120.4 (7.1) | 0.7–570 | 74.0 (5.3) |
DL-PCB 105 (ng/L) | 1,140 (195) | 115.0 (7.0) | 5–620 | 69.2 (4.0) |
DL-PCB 118 (ng/L) | 1,140 (195) | 582.7 (35.5) | 22–3,000 | 352.1 (19.6) |
DL-PCB 156 (ng/L) | 1,140 (195) | 163.3 (13.0) | 5–1,800 | 98.5 (5.7) |
DL-PCB 157 (ng/L) | 1,140 (195) | 60.4 (4.8) | 5–520 | 35.1 (2.1) |
DL-PCB 167 (ng/L) | 1,140 (195) | 55.2 (3.8) | 5–460 | 33.7 (1.9) |
DL-PCB 189 (ng/L) | 1,140 (195) | 25.6 (2.2) | 5–270 | 15.3 (0.9) |
ΣDL-PCBse (ng/L) | 1,140 (195) | 1,002 (59) | 47–4818 | 633.8 (33.3) |
Mercury (nmol/L) | 1,140 (195) | 132.1 (6.7) | 4.9–760 | 94.5 (5.0) |
Lead (µmol/L) | 1,140 (195) | 0.28 (0.01) | 0.04–1.5 | 0.23 (0.01) |
Age (years) | 1,140 (195) | 48.6 (0.5) | 35–72 | |
Weight (kg) | 1,124 (192) | 66.6 (1.0) | 37.6–118 | |
Height (cm) | 1,140 (195) | 152.3 (0.3) | 142–164 | |
Omega-3 PUFAs (%) | 1,140 (195) | 11.9 (0.2) | 1.7–19.5 | |
Omega-6 PUFAs (%) | 1,140 (195) | 23.3 (0.3) | 12.6–32.4 | |
Retinol (µmol/L) | 1,111 (191) | 2.16 (0.04) | 1.04–3.58 | |
Vitamin D (nmol/L) | 1,134 (194) | 30.1 (0.7) | 5.9–67.5 | |
Total plasma lipids (g/L) | 1,135 (194) | 6.4 (0.1) | 4.1–11.4 | |
Nf (%) | Nb | |||
Menopausal status | 1,139.7 | 195 | ||
Postmenopausal | 486.4 (42.7) | 79 | ||
Non-menopausal | 653.3 (57.3) | 116 | ||
Level of education | 1,093.3 | 191 | ||
None or primary school | 590.7 (54.0) | 103 | ||
Secondary or higher | 502.6 (46.0) | 88 | ||
Supplement useg | 1,139.6 | 195 | ||
Yes | 115.4 (10.1) | 19 | ||
No | 1,024.2 (89.9) | 176 | ||
Tobacco use | 1,131.4 | 193 | ||
Yes | 827.3 (73.1) | 144 | ||
No | 304.1 (26.9) | 49 | ||
Parity | 1,123.4 | 192 | ||
Yes | 1,057.7 (94.1) | 182 | ||
No | 65.7 (5.9) | 10 |
Weighted and rounded size
sample size
arithmetic mean
geometric mean
sum of DL-PCB nos. 105, 118, 156, 157, 167 and 189
weighted size
calcium and vitamin D supplements in the last 12 months.